Almac Forms Academia-Industry Collaboration to Develop Green Chemicals
Almac announces its high level involvement in a synthetic biology project to develop novel routes to chemicals. Other partners in the academic–industry collaboration include Bangor University (Wales) and Hockley International (manufacturer and exporter of environmental health and industrial chemical products).
A grant of £1 million has been awarded to the research team by the Biotechnology & Biological Sciences Research Council and Technology Strategy Board. The funding is specifically targeted at bringing a novel chemical produced via an enzymatic route from under-utilised natural oil to the market.
Almac is currently performing the research and development work at its Northern Ireland-based laboratories. The company is partnering with scientific experts from both the University’s College of Natural Sciences and Hockley to progress the project over a three year period.
Professor Tom Moody, Head of Biocatalysis & Isotope Chemistry at Almac, commented: “Almac has cultivated considerable enzyme technology experience and expertise over the past decade and collaboration in this research is especially important for the development of green processes in this industry. Our expert team of scientists are excited to work on this project as we recognise the opportunity for researchers across industry and academia to work more closely together, sharing skills and knowledge to deliver truly excellent research that can make an impact not just on this project but also the UK. Indeed, we are delighted to be at the forefront of such partnerships.”
“It will form a close collaboration between Almac, Hockley and the University’s School of Biological Sciences, Biocomposites Centre,” explains Dr Viacheslav Tverezovskiy who is leading this research at Bangor University.
Frank Howard, MD and owner of Hockley International adds “We look forward to starting this major 3-year project in synthetic biology along with Almac and Bangor University which promises to be most exciting and scientifically challenging for us all.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.